Zanzalintinib plus atezolizumab is first immunotherapy regimen to benefit patients with metastatic CRC

Authors

Publication Details

Journal
Cancer
Published
2026-02-01
DOI
https://doi.org/10.1002/cncr.70235
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Zanzalintinib plus atezolizumab is first immunotherapy regimen to benefit patients with metastatic CRC

Leah Lawrence
Cancer
Cancer Immunotherapy and Biomarkers
article

Zanzalintinib plus atezolizumab is first immunotherapy regimen to benefit patients with metastatic CRC

Leah Lawrence
article en

Abstract

No abstract available for this paper.
CancerVol. 132(3)
Good health and well-being
Openalex Percentile: Top 65%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Zanzalintinib plus atezolizumab is first immunotherapy regimen to benefit patients with metastatic CRC — Leah Lawrence · Cancer (2026) | TGRS Research Map | TGRS